BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29037604)

  • 21. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence.
    Zhao Y; Pan Z; Namburi S; Pattison A; Posner A; Balachander S; Paisie CA; Reddi HV; Rueter J; Gill AJ; Fox S; Raghav KPS; Flynn WF; Tothill RW; Li S; Karuturi RKM; George J
    EBioMedicine; 2020 Nov; 61():103030. PubMed ID: 33039710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma.
    Schneider M; Schüler J; Höfflin R; Korzeniewski N; Grüllich C; Roth W; Teber D; Hadaschik B; Pahernik S; Hohenfellner M; Duensing S
    Urol Oncol; 2014 Aug; 32(6):877-84. PubMed ID: 24929890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-144 inhibits the metastasis of gastric cancer by targeting MET expression.
    Liu J; Xue H; Zhang J; Suo T; Xiang Y; Zhang W; Ma J; Cai D; Gu X
    J Exp Clin Cancer Res; 2015 Apr; 34(1):35. PubMed ID: 25927670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary.
    Laprovitera N; Riefolo M; Porcellini E; Durante G; Garajova I; Vasuri F; Aigelsreiter A; Dandachi N; Benvenuto G; Agostinis F; Sabbioni S; Berindan Neagoe I; Romualdi C; Ardizzoni A; Trerè D; Pichler M; D'Errico A; Ferracin M
    Mol Oncol; 2021 Oct; 15(10):2732-2751. PubMed ID: 34075699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic regulation of HGF/Met receptor axis is critical for the outgrowth of bone metastasis from breast carcinoma.
    Bendinelli P; Maroni P; Matteucci E; Desiderio MA
    Cell Death Dis; 2017 Feb; 8(2):e2578. PubMed ID: 28151481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different growth and metastatic phenotypes associated with a cell-intrinsic change of Met in metastatic melanoma.
    Adachi E; Sakai K; Nishiuchi T; Imamura R; Sato H; Matsumoto K
    Oncotarget; 2016 Oct; 7(43):70779-70793. PubMed ID: 27683122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown primary).
    Lequin D; Fizazi K; Toujani S; Souquère S; Mathieu MC; Hainaut P; Bernheim A; Praz F; Busson P
    BMC Cancer; 2007 Dec; 7():225. PubMed ID: 18088404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin.
    Herynk MH; Tsan R; Radinsky R; Gallick GE
    Clin Exp Metastasis; 2003; 20(4):291-300. PubMed ID: 12856716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c.
    MacDougall CA; Vargas M; Soares CR; Holzer RG; Ide AE; Jorcyk CL
    Prostate; 2005 Jul; 64(2):139-48. PubMed ID: 15678502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Silencing the MET oncogene leads to regression of experimental tumors and metastases.
    Corso S; Migliore C; Ghiso E; De Rosa G; Comoglio PM; Giordano S
    Oncogene; 2008 Jan; 27(5):684-93. PubMed ID: 17684486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
    Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
    Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer.
    Yeh CY; Shin SM; Yeh HH; Wu TJ; Shin JW; Chang TY; Raghavaraju G; Lee CT; Chiang JH; Tseng VS; Lee YC; Shen CH; Chow NH; Liu HS
    BMC Cancer; 2011 Apr; 11():139. PubMed ID: 21496277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer of unknown primary site: missing primary or missing biology?
    Pentheroudakis G; Briasoulis E; Pavlidis N
    Oncologist; 2007 Apr; 12(4):418-25. PubMed ID: 17470684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Karyopherin β1 deletion suppresses tumor growth and metastasis in colorectal cancer (CRC) by reducing MET expression.
    Zhang Y; Li KF
    Biomed Pharmacother; 2019 Dec; 120():109127. PubMed ID: 31629952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells.
    Yin B; Liu Z; Wang Y; Wang X; Liu W; Yu P; Duan X; Liu C; Chen Y; Zhang Y; Pan X; Yao H; Liao Z; Tao Z
    Oncol Rep; 2017 Jun; 37(6):3209-3218. PubMed ID: 28440432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.
    Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Sugiyama M; Watanabe T
    Oncol Rep; 2014 Jul; 32(1):57-64. PubMed ID: 24839940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Familial risks in cancer of unknown primary: tracking the primary sites.
    Hemminki K; Ji J; Sundquist J; Shu X
    J Clin Oncol; 2011 Feb; 29(4):435-40. PubMed ID: 21189391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SOX13 promotes colorectal cancer metastasis by transactivating SNAI2 and c-MET.
    Du F; Li X; Feng W; Qiao C; Chen J; Jiang M; Qiu Z; Qian M; Tian D; Nie Y; Fan D; Wu K; Xia L
    Oncogene; 2020 Apr; 39(17):3522-3540. PubMed ID: 32111984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activating mutation in MET oncogene in familial colorectal cancer.
    Neklason DW; Done MW; Sargent NR; Schwartz AG; Anton-Culver H; Griffin CA; Ahnen DJ; Schildkraut JM; Tomlinson GE; Strong LC; Miller AR; Stopfer JE; Burt RW
    BMC Cancer; 2011 Oct; 11():424. PubMed ID: 21970370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition.
    Verginelli F; Pisacane A; Gambardella G; D'Ambrosio A; Candiello E; Ferrio M; Panero M; Casorzo L; Benvenuti S; Cascardi E; Senetta R; Geuna E; Ballabio A; Montemurro F; Sapino A; Comoglio PM; Boccaccio C
    Nat Commun; 2021 May; 12(1):2498. PubMed ID: 33941777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.